MicroRNA-26a/b and their host genes cooperate to inhibit the G1/S transition by activating the pRb protein

Ying Zhu1,2, Yang Lu2, Qi Zhang1, Jing-Jing Liu2, Tuan-Jie Li1, Jian-Rong Yang2, Chunxian Zeng2 and Shi-Mei Zhuang1,2,*

1Key Laboratory of Liver Disease of Guangdong Province, The Third Affiliated Hospital of Sun Yat-sen University and 2Key Laboratory of Gene Engineering of the Ministry of Education, School of Life Sciences, Sun Yat-sen University, Guangzhou 510275, P.R. China

Received May 19, 2011; Revised November 24, 2011; Accepted December 9, 2011

ABSTRACT

The functional association between intronic miRNAs and their host genes is still largely unknown. We found that three gene loci, which produced miR-26a and miR-26b, were embedded within introns of genes coding for the proteins of carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase (CTDSP) family, including CTDSPL, CTDSP2 and CTDSP1. We conducted serum starvation-stimulation assays in primary fibroblasts and two-thirds partial-hepatectomies in mice, which revealed that miR-26a/b and CTDSP1/2/L were expressed concomitantly during the cell cycle process. Specifically, they were increased in quiescent cells and decreased during cell proliferation. Furthermore, both miR-26 and CTDSP family members were frequently downregulated in hepatocellular carcinoma (HCC) tissues. Gain- and loss-of-function studies showed that miR-26a/b and CTDSP1/2/L synergistically decreased the phosphorylated form of pRb (ppRb), and blocked G1/S-phase progression. Further investigation disclosed that miR-26a/b directly suppressed the expression of CDK6 and cyclin E1, which resulted in reduced phosphorylation of pRb. Moreover, c-Myc, which is often upregulated in cancer cells, diminished the expression of both miR-26 and CTDSP family members, enhanced the ppRb level and promoted the G1/S-phase transition. Our findings highlight the functional association of miR-26a/b and their host genes and provide new insight into the regulatory network of the G1/S-phase transition.

INTRODUCTION

MicroRNAs (miRNAs) belong to a class of endogenously expressed, small non-coding RNAs that cause translation-repression and/or mRNA destabilization by binding to the 3'-untranslated regions (3'-UTRs) of the target mRNAs (1). Approximately 40% of all miRNAs are located within intronic regions of protein-coding transcriptional units (TUs) (2). Analysis of 175 human miRNAs across 24 different human organs reveals that the expression of intronic miRNAs largely coincides with the transcription of their host TUs (3), indicating that the intronic miRNAs and their host genes may be co-regulated and are generated from a common precursor transcript.

Emerging evidence suggests that intronic miRNAs may be functionally associated with their host genes. Few reports suggest that there is an antagonizing effect of the intronic miRNA on the function of its host gene, as with miR-218 (4) and miR-10 (5,6). The secreted Slit ligands and their Robo receptors constitute a Slit–Robo signaling pathway that controls the directed migration of neurons and vascular endothelial cells during embryonic development. miR-218 is localized in the intron of the Slit gene, and similar expression patterns are observed between miR-218 and Slit in different tissues. Furthermore, miR-218 inhibits the expression of Robo1 and Robo2, which generates a negative feedback loop in response to...
Slit gene activation and thereby contributes to the ‘fine-tuning’ of the Slit–Robo pathway (4). Another example of miRNAs associating with their host genes are the miR-10 family members, whose gene loci are retained within the Hox clusters that encode for developmental regulators. Interestingly, Hox transcripts are targets of the miR-10 family members in several species (5,6). However, there may be a synergistic effect of miRNA with its host gene. miR-33a/b act in concert with their SREBP (sterol regulatory element-binding protein) host genes to control cholesterol homeostasis (7–10). miR-208a/b and their Myh6/7 host genes cooperate to govern myosin expression and muscle performance (11). The miR-106–25 cluster and its host gene MCM7 transforms cells synergistically (12). miR-151 and the host gene FAK work together to enhance the motility and spreading of hepatocellular carcinoma (HCC) cells (13). An extensive investigation of the functional association between intronic miRNAs and their host genes will help to disclose the elaborate regulatory network of cellular activity.

Over the course of evolution, the genomic loci of miR-26a and miR-26b have been localized to the introns of genes coding for the proteins of carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase (CTDSP) family. However, the functional association of miR-26 with CTDSP family members and the biological significance of this association remain unknown. Herein, we show that miR-26 family members are expressed concomitantly with their host genes in physiological and pathological conditions. We further disclose that miR-26a/b and their host genes cooperate to block the G1/S-phase transition by synergistically activating the pRb protein. Our findings highlight the functional association of miR-26a/b and their host genes and the potential implication of this association in physiological and pathological processes.

MATERIALS AND METHODS

Cell lines and human tissue specimens

Cancer cell lines, which were derived from the liver (MHCC-97L, HepG2 and Huh7), lung (95D), breast (MCF7) and cervix (HeLa), were maintained in Dulbecco’s modified Eagle’s medium (DMEM, Hyclone, Logan, UT, USA) supplemented with 10% fetal bovine serum (FBS, HyClone, Thermo Fisher Scientific, Austria). Primary fibroblasts were isolated from human neonatal foreskin using an optimized enzymatic dissociation procedure (14) and grown in RPMI 1640 medium (Hyclone) supplemented with 10% FBS, penicillin and streptomycin. Normal liver tissues were collected from patients undergoing resection of hepatic hemangiomas, and paired HCC and adjacent non-tumor liver tissues were obtained from patients undergoing HCC resection at the Cancer Center of Sun Yat-sen University. Both tumor and non-tumor tissues were histologically confirmed. No local or systemic treatments had been conducted before the operations. Informed consent was obtained from each patient, and the study was approved by the Institute Research Ethics Committee at the Cancer Center of Sun Yat-sen University.

Two-thirds partial hepatectomy in mice

Eight- to twelve-week-old male C57BL/6 mice were used. Two-thirds of the liver was surgically removed under chloral hydrate anesthesia as previously described (15). All experimental procedures involving animals were in accordance with the Guide for the Care and Use of Laboratory Animals (NIH publications Nos. 80-23, revised 1996) and were performed according to the institutional ethical guidelines for animal experiments.

RNA oligoribonucleotides and plasmids

hsa-miR-26a/b (Pre-miR miRNA Precursor Product, cat. AM17100) and NC (Pre-miR Negative Control #2, cat. AM17111) were purchased from Applied Biosystems (Foster City, CA, USA). Other RNA oligoribonucleotides (Supplementary Table S1) were obtained from GenePharma (Shanghai, P.R. China). The siRNAs targeting human CDK6 (GenBank accession no. NM_001259), CCNE1 (NM_001238), c-Myc (NM_002467), CTDSP1 (NM_012198 and NM_182642), CTDSP2 (NM_005730) and CTDSL (NM_005808 and NM_00108392) transcripts were designated as siCDK6, siCCNE1, siMyC, siCTDSP1, siCTDSP2 and siCTDSL, respectively. The anti-miR-26, with a sequence complementary to mature miR-26b, was a 2'-O-methyl-modified oligoribonucleotide. The anti-miR-C, which is non-homologous to any human genome sequences, was used as a negative control for anti-miR-26.

The vectors used (details in Supplementary Materials and Methods) included firefly luciferase reporter plasmids that contained a wild-type or mutant 3'-UTR segment of human CDK6 or CCNE1, and pc3-gab-CDK6, pc3-gab-CCNE1, pc3-gab-c-Myc, pc3-gab-CTDSP1, pc3-gab-CTDSP2 and pc3-gab-CTDSL, which expressed CDK6, CCNE1, c-Myc, CTDSP1, CTDSP2 and CTDSL, respectively.

Cell transfection

RNA oligos were transfected using Lipofectamine RNAiMAX (Invitrogen, Carlsbad, CA, USA). A final concentration of 50 nM duplex or 200 nM miRNA inhibitor was used unless indicated. RNA transfection efficiency is ~70–80% (16), and overexpression of a miRNA mimic persists for at least 4 days (17). TurboFect™ in vitro Transfection Reagent (Fermentas, Hanover, MD, USA) was used for transfection of HepG2 with pc3-gab or pc3-gab-c-Myc. Other transfection of plasmid DNA with or without RNA oligos was performed using Lipofectamine 2000 (Invitrogen).

Cell cycle analysis

All cell cycle analyses were performed using a detergent-containing hypotonic solution (Krishan’s reagent) and fluorescence-activated cell sorting (FACS) (Gallios, Beckman Coulter, Miami, FL, USA) as previously
reported (18). Nuclear debris and overlapping nuclei were gated out.

Luciferase reporter assay
MHCC-97L cells grown in a 48-well plate were co-transfected with 10 ng of firefly luciferase reporter comprising a wild-type or mutant 3' UTR of the target gene. 2 ng of pRL-TK (Promega, Madison, WI, USA) and 10 nM of RNA oligoribonucleotides. A luciferase assay was performed as previously reported (16). The pRL-TK vector that provided the constitutive expression of Renilla luciferase was used as an internal control to correct for the differences in transfection and harvest efficiencies. Transfection was performed in duplicate and was repeated at least three times in independent experiments.

Analysis of gene expression
Semiquantitative RT–PCR and real-time quantitative RT–PCR (qPCR) were performed to evaluate the RNA level. Expression of CTDSPL/2/1 was quantified by THUNDERBIRD SYBR qPCR Mix (QPS-201, TOYOBO, Japan), using β-actin and GAPDH as reference genes. Expression of miR-26a/b was quantified using the miRCURY LNA Universal RT microRNA PCR system (Exiqon, Vedbaek, Denmark) when β-actin and GAPDH were used as internal standards, or by a TaqMan MicroRNA Assay kit (Applied Biosystems, Foster City, CA, USA) when U6B was used as reference. Western blot and immunohistochemical staining were performed to detect the protein level (details in Supplementary Materials and Methods).

Bioinformatic tools and statistical analysis
The databases used for bioinformatic analysis are described under Supplementary Materials and Methods.

RESULTS
miR-26 family members are expressed concomitantly with their host genes in physiological and pathological conditions
Since the birth and death rates of miRNA genes are rather high over the course of evolution (19), the co-localization of some miRNAs and their host genes may be a coincidence. However, if a miRNA family always resides within the gene loci of a protein family, they are more likely to be physiologically relevant. To identify miRNAs that exhibit a functional association with their host genes, we first mapped the gene loci of miRNA families to hosting TUs. Among 108 miRNA families with at least two members that have been identified in human, 13 of them were mapped to the introns of protein families (Supplementary Table S2). Except for miR-128, miR-506, miR-548 and miR-1233 families, the colocalization of the other nine miRNA families with protein-coding genes has been previously noted (3–7,9–11,20,21). Notably, miR-26, miR-103, miR-33 and miR-153 family members displayed a perfect one-to-one colocalization with the members of their host protein family (Table 1).

The miR-26 family comprises miR-26a and miR-26b; they are transcribed from three genomic loci, miR-26a-1, miR-26a-2 and miR-26b, which reside in the introns of genes coding for the CTDSPL, CTDSPL2 and CTDSPL1 proteins, respectively. The basic arrangement of these miRNAs in the CTDSPL/2/1 genes has remained constant throughout vertebrate evolution (Supplementary Figure S1). It has been reported that CTDSPL dephosphorylates the phosphorylated form of pRb (ppRb) and thereby presumably leads to the arrest of the cell cycle at the G1/S boundary (22). Furthermore, expression of miR-26a causes increased G1-cells (23–25). More importantly, among the predicted targets of miR-26a/b, we found an enrichment of G1/S transition-related genes (3.9-fold overrepresentation, \( P = 0.0184 \); Supplementary Table S3).

Based on the above pieces of evidence, we first examined whether miR-26a/b and CTDSPL/2/1 were expressed concomitantly during the cell cycle process using a serum starvation–stimulation assay. Human primary fibroblasts were serum deprived for 48 h and stimulated to induce S-phase entry by serum re-addition. The cells were synchronized in G0-phase by serum deprivation. Within 4 h after serum addition, the cells remained in G1-phase, whereas a large proportion of cells entered S-phase at 16 h and progressed to G2/M-phase at 24 h (Figure 1A). The expression of miR-26a/b and CTDSPL/2/1 increased after serum deprivation, when the cell cycle was arrested at G0-phase, and decreased quickly after serum stimulation (Figure 1B, Supplementary Figure S2A). Furthermore, miR-26a/b and CTDSPL/2/1 displayed a similar trend of expression over time (Figure 1B, Supplementary Figure S2A). To confirm the findings from the in vitro study, we conducted the two-thirds partial hepatectomy in mice, a physiological liver regeneration model that is often used to study the cell cycle in vivo. It has been showed that the majority of the hepatic cells were
undergoing proliferation around 36 h post-hepatectomy (15,26,27). Interestingly, we found that the expression of miR-26a/b and CTDSP1/2/L coordinately reduced at 24 h and 36 h post-hepatectomy, and began to elevate around 48 h, once cellular proliferation declined (Figure 1C, Supplementary Figure S2B). Furthermore, miR-26 and CTDSP family members were frequently down-regulated in human HCC tissues (Figure 2A, Supplementary Figure S3A), and a similar expression pattern was observed between miR-26a and miR-26b

| Table 1. Perfect one-to-one colocalization between miRNA and protein family members |
|---|
| miRNA family | miRNA family ID | Protein family ID | Colocalization of miRNA and protein family members |
| miR-26 | MIPF0000043 | ENSFM00500000269811 | hsa-miR-26a-1—CTDSP1 |
| miR-103 | MIPF0000024 | ENSFM00260000050538 | hsa-miR-26b—CTDSP1 |
| miR-33 | MIPF0000070 | ENSFM00250000001438 | hsa-miR-33a—SREBF2 |
| miR-153 | MIPF0000050 | ENSFM00260000050522 | hsa-miR-153-1—PTPRN |

^miRNA family ID was derived from miRBase (release 16.0).

Protein family ID was obtained from Ensembl Genome Browser (release 60).
Expression of miR-26a/b can be suppressed by c-Myc in lymphoma cells (25,28). We also found that c-Myc silencing increased endogenous miR-26a/b and CTDSP1/2/L levels in HCC cells (Figure 3A), whereas overexpression of c-Myc downregulated the expression of miR-26a/b and CTDSP1/2/L (Figure 3B). These results indicate that miR-26a/b and CTDSP1/2/L may be co-regulated in both physiological and pathological processes.

(Supplementary Figure S4) and between miR-26a/b and their respective host genes (Figure 2B, Supplementary Figure S3B).

Expression of miR-26a/b can be suppressed by c-Myc in lymphoma cells (25,28). We also found that c-Myc silencing increased endogenous miR-26a/b and CTDSP1/2/L levels in HCC cells (Figure 3A), whereas overexpression of c-Myc downregulated the expression of miR-26a/b and CTDSP1/2/L (Figure 3B).

These results indicate that miR-26a/b and CTDSP1/2/L may be co-regulated in both physiological and pathological processes.

Figure 2. miR-26a/b are expressed concomitantly with CTDSP1/2/L in a pathological condition. (A) Analysis of mature miR-26a/b and CTDSP1/2/L expression in 32 paired HCC and adjacent non-tumor tissues by qPCR. T, HCC tissue and N, adjacent non-cancerous tissue. The y-axis indicates the relative level of miR-26a/b and CTDSP1/2/L. The boxes represent the interquartile range (25–75th centiles). The horizontal line inside the box indicates the median. The vertical whiskers extend to the maximum and minimum values. (B) The correlation between expression levels of miR-26a/b and their respective host genes in 32 paired HCC and adjacent non-tumor tissues. The expression status of miR-26a/b and CTDSP1/2/L is shown in a log 2 scale. For (A and B), statistical analysis was performed by Wilcoxon matched-pairs signed-ranks test and Spearman’s correlation coefficient, respectively. The expression levels of miR-26a/b and CTDSP1/2/L were normalized to β-actin.

Figure 3. The expression of miR-26a/b and CTDSP1/2/L is co-regulated by c-Myc. (A) Effect of c-Myc silencing on mature miR-26a/b and CTDSP1/2/L expression in HepG2 cells. Forty-eight hours after transfection with 20 nM indicated RNA duplex, cells were analyzed by qPCR. NC, negative control; siMyc, siRNA targets c-Myc. (B) Effect of c-Myc overexpression on mature miR-26a/b and CTDSP1/2/L levels in HepG2 cells. Cells were transfected with empty pc3-gab vector (indicated as EGFP) or pc3-gab-c-Myc (Myc) for 48 h, then subjected to qPCR. The expression levels of miR-26a/b and CTDSP1/2/L were normalized to β-actin. *P < 0.05; **P < 0.01.
miR-26a/b function synergistically with their host genes to block G1/S transition

Next, we evaluated the potential roles of miR-26a/b and their host genes in the regulation of G1/S transition and determined the functional significance of their association. Overexpression of either miR-26a or miR-26b resulted in a marked accumulation of the G1-population in different cancer cell lines derived from the liver (MHCC-97L, HepG2 and Huh7), lung (95D), breast (MCF7) and cervix (HeLa) (Figure 4A, Supplementary Figure S5), indicating a ubiquitous role for miR-26a/b in cell cycle control. Serum starvation–stimulation assays further revealed that most of the miR-26a/b-transfectants remained in G1-phase (Figure 4B), while a large proportion of NC-transfected cells already entered S-phase after serum re-addition, suggesting that miR-26a/b can block G1/S transition.

To confirm the results from the gain-of-function study, loss-of-function analysis was performed using anti-miR-26, which could knockdown the expression of miR-26a and miR-26b (Supplementary Figure S6). Compared with the control group (anti-miR-C), transfection of anti-miR-26 only caused a slight decrease in G1-cells (Figure 4C), which might be explained by the low basal level of miR-26 in these cells (Supplementary Figure S7). Thus, we evaluated the effect of miR-26 inhibition using a c-Myc-knockdown model in which c-Myc silencing caused elevated endogenous miR-26a/b (Figure 3A). As shown in Figure 4C, knockdown of c-Myc resulted in an increase in the G1-population, whereas this effect was attenuated when miR-26a/b was inhibited by anti-miR-26.
Although it has been shown that CTDSPL may arrest the cell cycle at G1-phase by dephosphorylating ppRb, the effect of the other CTDSP family members on the cell cycle is still unknown. Therefore, we examined whether all host genes of miR-26a/b play a regulatory role in G1/S transition. Expression of either of CTDSP1/2/L induced G1-arrest (Figure 4D), whereas silencing either of them promoted G1/S progression (Figure 4E). Furthermore, the effect of triple-overexpression or -knockdown of CTDSP1/2/L was more pronounced than single-expression or -knockdown of either one (Figure 4D and E).

We further determined whether a synergistic effect exists between miR-26a/b and their host genes in the context of cell cycle regulation. The G1-arrest was more evidenced when miR-26a/b and CTDSP1/2/L were co-expressed (Figure 5A). Consistently, simultaneous suppression of miR-26a/b and their host genes resulted in a more pronounced G1/S progression in siMyc-transfectants (Figure 5B).

Collectively, these data implicate that miR-26a/b can function synergistically with their host genes to block G1/S transition.

miR-26a/b and their host genes block G1/S transition by synergistically activating the pRb protein

We then explored the molecular mechanisms responsible for the observed function of miR-26a/b and their host genes. The predicted targets of miR-26a/b included four G1/S transition-related genes, CDK6, cyclin E1, cyclin D2 and cyclin E2 (Supplementary Table S3), which are crucial components of the cell cycle that initiate G1/S progression. Since cyclin D2 and cyclin E2 are the known targets of miR-26 (24), we focused on CDK6 and cyclin E1. We identified one putative miR-26-binding site in the 3'-UTR of CCNE1 and two sites in the 3'-UTR of CDK6 (Supplementary Figure S8) using TargetScan.

A dual-luciferase reporter system revealed that transfection of miR-26a/b significantly suppressed the firefly luciferase activity of the reporter containing the wild-type, but not the mutant binding site of the 3'-UTR (Figure 6A), indicating that miR-26 may suppress gene expression through its binding sequences at the 3'-UTR of target genes. Further investigation showed that miR-26a/b could also diminish endogenous expression of both CDK6 and cyclin E1 proteins (Figure 6B). Moreover, downregulation of miR-26a/b was statistically correlated with overexpression of CDK6 and cyclin E1 in HCC tissues (Figure 6C). These data suggest that CDK6 and cyclin E1 are direct targets of miR-26a/b.

The involvement of CDK6 and cyclin E1 in miR-26-regulated G1/S transition was then addressed. Silencing of either CDK6 or cyclin E1 (Figure 6B) led to the arrest of the cell cycle in G1-phase (Figure 6D), which was the phenocopy of the result of enhanced miR-26 expression, whereas overexpression of CDK6 and cyclin E1 abrogated miR-26-induced G1-arrest (Figure 6E).

It is well known that CDK6, cyclin E1, cyclin D2 and cyclin E2 initiate the phosphorylation of pRb, which in turn, results in pRb inactivation and the release of E2F. E2F consequently transactivates the genes required for S-phase entry. Therefore, we explored whether miR-26 could attenuate these events. Introduction of miR-26 caused a prominent decrease of ppRb (Figure 7A), whereas miR-26 inhibition enhanced the expression of CDK6 and cyclin E1 and increased the level of ppRb in siMyc-transfectants (Figure 7B). These results imply that miR-26 may activate the pRb protein by suppressing CDK6 and multiple G1-phase cyclins.

Interestingly, expression of CTDSP1/2/L significantly decreased the level of ppRb (Figure 7C, lanes 1 and 2), and a synergistic repression was observed when CTDSP1/2/L were co-expressed with miR-26a/b (Figure 7C). Consistently, knockdown of CTDSP1/2/L increased the amount of ppRb (Figure 7D, lanes 2 and 4), and the synergistic effect was also found when both miR-26a/b and their host genes were inhibited (Figure 7D).

These findings indicate that miR-26a/b and their host genes cooperate to activate pRb protein, and in turn, block the G1/S transition.
DISCUSSION

Although 40% of all miRNAs are located within intronic regions of protein-coding TUs (2), the functional association between miRNAs and their host genes remains unclear. In this study, we found that miR-26a/b were expressed concomitantly with their host genes CTDSP1/2/L in both physiological and pathological processes. Moreover, miR-26a/b and CTDSP1/2/L synergistically blocked the G1/S transition by activating the same protein, pRb.

The pRb-pathway acts as a master checkpoint in cell cycle progression. Cyclic phosphorylation and dephosphorylation of the pRb protein control the entry of cells into S-phase. Here, we found a synergistic effect of miR-26a/b and CTDSP1/2/L in decreasing the ppRb level and blocking the G1/S progression. Both miR-26a and miR-26b reduced the amount of ppRb by repressing the CDK and cyclins that mediate the phosphorylation of pRb. On the other hand, CTDSP1/2/L may directly dephosphorylate ppRb because CTDSP1/2/L possess...
Phosphatase activity (29–31). It is intriguing to find that miR-26a/b and their host genes regulate pRb phosphorylation through different molecular mechanisms. The cooperation of miR-26 and CTDSP1/2/L in the pRb pathway may provide a ‘double guarantee system’ for the activation of the pRb protein, which guards cells from excessive proliferation. Our observations give new insight into the elaborate control of G1/S transition and suggest the existence of a single gene locus that harbors two independent, but cooperating growth-suppressive elements.

c-Myc is essential for progression from G0/G1 to S-phase (32). It has been demonstrated that c-Myc activates the positive regulator of G1/S transition, including cyclin D1, cyclin D2, cyclin E1, CDK4, CDC25A and E2F, during cell cycle progression (32). Here, we showed that c-Myc could downregulate both miR-26 and CTDSP family members, which enhanced ppRb levels and ultimately promoted the G1/S transition. Our findings disclose a novel mechanism by which c-Myc promotes cell cycle progression by suppressing one gene locus that carries both miRNA and protein-coding gene.

The serum starvation–stimulation assay in primary fibroblasts and the two-thirds partial hepatectomy in mice revealed the increased expression of miR-26a/b and CTDSP1/2/L in quiescent cells and the downregulation of both families during cell proliferation. Furthermore, the levels of miR-26a/b and CTDSP1/2/L were reduced in HCC tissues. These data suggest that miR-26a/b and CTDSP1/2/L may keep fibroblasts and hepatocytes in a non-dividing state, and their deregulation may promote malignant transformation. The underlying mechanism responsible for the decreased expression of these two families in HCC is still unknown. Notably, c-Myc activation is a common event in HCC (33). Amplification of chromosome 8q24, in which c-Myc is located, and upregulation of c-Myc and its downstream target genes are observed in viral and alcohol-related HCC (34). Studies from animal models have also revealed that c-Myc overexpression promotes HCC development (33). Thus, abnormal c-Myc activation may represent an important mechanism underlying the downregulation of miR-26a/b and CTDSP1/2/L. In addition, CTDSP1/miR-26b is located at chromosome 2q35, a region that is frequently deleted in human cancers, especially HCC (35). We were also able to computationally map CpG islands in the promoter regions (between 2000 and 600 bp) of CTDSP1/2/L and miR-26a/b. Therefore, deletion and promoter hypermethylation may also account for the reduced expression of CTDSP1/2/L and miR-26a/b in HCC.

CTDSP1, CTDSP2 and CTDSPL belong to a protein family of small C-terminal domain (CTD) phosphatases, also known as the SCP family. They can negatively regulate RNA polymerase II (RNAPII) by dephosphorylating its CTD on Ser-5 in vitro (31), and also function as transcriptional co-repressors that inhibit the transcription of neuronal gene in non-neuronal cells (36).
Growing evidence also suggests that CTDSP1/2/L act as phosphatases of Smad1, Smad2/3 and snail (29,30). It has been demonstrated that CTDSP1 dephosphorylates the ppRb protein and presumably regulates the cell cycle. CTDSP1 is homozygously deleted in ~15% of cervical carcinomas, and CTDSP1 suppresses the ability of renal carcinoma cells to form colonies in vitro and to develop tumors in SCID mice (22). However, the effect of the other two family members, CTDSP1 and CTDSP2, on the cell cycle and tumorigenesis is still unknown. Here, we showed that CTDSP1, CTDSP1 and CTDSP2 could block G1/S progression, and all CTDSP family members were downregulated in HCC tissues, suggesting that CTDSP1/2/L dysfunction may be involved in hepatocarcinogenesis.

In summary, we disclosed the cooperative effect of miR-26a/b and their host genes CTDSP1/2/L in the cell cycle control and their potential implication in physiological and pathological processes. Our findings highlight the functional association of miR-26a/b and their host genes, provide new insight into the regulatory network of the cell cycle and open the possibility for future therapeutic intervention.

SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online: Supplementary Methods, Supplementary Tables S1–S3, Supplementary Figures S1–S8.

ACKNOWLEDGEMENTS
We thank Qi He for the help of statistical analysis. We are grateful to the Bank of Tumor Resources and Prof. Yunfei Yuan in Department of Hepatobiliary Oncology, Cancer Center, Sun Yat-sen University for providing tissue specimens and the clinical information of patients.

FUNDING
This work was supported by the Ministry of Science and Technology of China (2010CB912803, 2011CB811305); National Natural Science Foundation of China (30870964, 30925036); and the Ministry of Health of China (2012ZX10002-011). Funding for open access charge: grant from the Ministry of Science and Technology of China (2010CB912803).

Conflict of interest statement. None declared.

REFERENCES
1. Bartel,D.P. (2009) MicroRNAs: target recognition and regulatory functions. Cell, 136, 215–233.
2. Kim,V.N., Han,J. and Shim,M.C. (2009) Biogenesis of small RNAs in animals. Nat. Rev. Mol. Cell Biol., 10, 126–139.
3. Baskerville,S. and Bartel,D.P. (2005) Microarray profiling of microRNAs reveals frequent coexpression with neighboring miRNAs and host genes. RNA, 11, 241–247.
4. Small,E.M., Sutherland,L.B., Rajagopalan,K.N., Wang,S. and Olson,E.N. (2010) MicroRNA-218 regulates vascular patterning by modulation of Slit-Robo signaling. Circ. Res., 107, 1336–1344.
5. Lund,A.H. (2010) miR-10 in development and cancer. Cell Death Differ., 17, 209–214.
6. Woltering,J.M. and Durston,A.J. (2008) MiR-10 represses HoxB1a and HoxB3a in zebrafish. PLoS One, 3, e1396.
7. Gerin,L., Clerbaux,L.A., Haumont,O., Lantier,N., Das,A.K., Burant,C.F., Leclercq,I.A., MacDougall,O.A. and Bommer,G.T. (2010) Expression of miR-33 from an SREBP2 intron inhibits cholesterol export and fatty acid oxidation. J. Biol. Chem., 285, 33652–33661.
8. Horie,T., Ono,K., Horiguchi,M., Nishi,H., Nakamura,T., Nagao,K., Kinoshita,M., Kuwabara,Y., Marusawa,H., Iwanaga,Y. et al. (2010) MicroRNA-33 encoded by an intron of sterol regulatory element-binding protein 2 (Srebp2) regulates HDL in vivo. Proc. Natl Acad. Sci. USA, 107, 17321–17326.
9. Najafi-Shoushti,S.H., Kristo,F., Li,Y., Shioda,T., Cohen,D.E., Gerstzen,R.E. and Naar,A.M. (2010) MicroRNA-33 and the SREBP host genes cooperate to control cholesterol homeostasis. Science, 328, 1566–1569.
10. Rayner,K.J., Suarez,Y., Davalos,A., Parathath,S., Fitzgerald,M.L., Tamehiro,N., Fisher,E.A., Moore,K.J. and Fernandez-Hernando,C. (2010) MiR-33 contributes to the regulation of cholesterol homeostasis. Science, 328, 1570–1573.
11. van Rooij,E., Quiat,D., Johnson,B.A., Sutherland,L.B., Qi,X., Richardson,J.A., Kelm,R.J. and Olson,E.N. (2009) A family of microRNAs encoded by myosin genes governs myosin expression and muscle performance. Dev. Cell, 17, 662–673.
12. Poliseno,L., Salmena,L., Riccardi,V., Fornari,F., Song,M.S., Hobbs,R.M., Sportorelli,P., Varmeh,S., Egia,A., Fedele,G. et al. (2010) Identification of the miR-106b~25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation. Sci. Signal, 3, a29.
13. Ding,J., Huang,S., Wu,S., Zhao,Y., Liang,L., Yan,M., Ge,C., Yao,J., Chen,T., Wan,D. et al. (2010) Gain of miR-151 on chromosome 8q24.3 facilitates tumour cell migration and spreading through downregulating RhoGDIa. Nat. Cell Biol., 12, 390–399.
14. Veelken,H., Jesuiter,H., Mackensen,A., Kulmburg,P., Schultz,J., Rosenthal,F., Mertelmann,R. and Lindemann,A. (1994) Primary fibroblasts from human adults as target cells for ex vivo gene transfection and gene therapy. Hum. Gene Ther., 5, 1203–1210.
15. Mitchell,L. and Willenbring,H. (2008) A reproducible and well-tolerated method for 2/3 partial hepatectomy in mice. Nat. Protocols, 3, 1167–1170.
16. Su,H., Yang,J.R., Xu,T., Huang,J., Xu,L., Yuan,Y. and Zhuang,S.M. (2009) Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity. Cancer Res., 69, 1135–1142.
17. Xiong,Y., Fang,J.H., Yun,J.P., Yang,J., Zhang,Y., Jia,W.H. and Zhuang,S.M. (2010) Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma. Hepatology, 51, 836–845.
18. Wang,W.Z., Cheng,J., Luo,J. and Zhuang,S.M. (2008) Abrogation of G2/M arrest sensitizes curcumin-resistant hepatoma cells to apoptosis. FEBS Lett., 582, 2689–2695.
19. Lu,J., Shen,Y., Wu,Q., Kumar,S., He,B., Shi,S., Carthew,R.W., Wang,S.M. and Wu,C.I. (2008) The birth and death of microRNA genes in Drosophila. Nat. Genet., 40, 351–355.
20. Wilfird,B.R., Wang,W.X. and Nelson,P.T. (2007) Energizing miRNA research: a review of the role of miRNAs in lipid metabolism, with a prediction that miR-103/107 regulates human metabolic pathways. Mol. Genet. Metab., 91, 209–217.
21. Rodrigo,A., Griffiths-Jones,S., Ashurst,J.L. and Bradley,A. (2004) Identification of mammalian microRNA host genes and transcription units. Genome Res., 14, 1902–1910.
22. Kashiwaba,Y.I., Li,J., Wang,E., Senchenko,V.N., Protopopov,A., Malyukova,A., Kutsenko,A.S., Kadyrova,E., Zabarovska,V.I., Muravenko,O.V. et al. (2004) RBPS3 (HYA2) is a tumor suppressor gene implicated in major epithelial malignancies. Proc. Natl Acad. Sci. USA, 101, 4906–4911.
23. Lu,J., He,M.L., Wang,L., Chen,Y., Liu,X., Dong,Q., Chen,Y.C., Peng,Y., Yao,K.T., Kung,H.F. et al. (2011) MiR-26a inhibits cell growth and tumorigenesis of nasopharyngeal carcinoma through repression of EZH2. Cancer Res., 71, 225–233.
24. Kota, J., Chivukula, R. R., O'Donnell, K. A., Wentzel, E. A., Montgomery, C. L., Hwang, H. W., Chang, T. C., Vivekanandan, P., Torbenson, M., Clark, K. R. et al. (2009) Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. *Cell*, 137, 1005–1017.

25. Sander, S., Bullinger, L., Klapproth, K., Fiedler, K., Kestler, H. A., Barth, T. F., Moller, P., Stilgenbauer, S., Pollack, J. R. and Wirth, T. (2008) MYC stimulates EZH2 expression by repression of its negative regulator miR-26a. *Blood*, 112, 4202–4212.

26. Taub, R. (2004) Liver regeneration: from myth to mechanism. *Nat. Rev. Mol. Cell Biol.*, 5, 836–847.

27. Matsuo, T., Yamaguchi, S., Mitsui, S., Emi, A., Shimoda, F. and Okamura, H. (2003) Control mechanism of the circadian clock for timing of cell division in vivo. *Science*, 302, 255–259.

28. Chang, T. C., Yu, D. L., Wentzel, E. A., Arking, D. E., West, K. M., Dang, C. V., Thomas-Tikhonenko, A. and Mendell, J. T. (2008) Widespread microRNA repression by Myc contributes to tumorigenesis. *Nat. Genet.*, 40, 43–50.

29. Wu, Y., Evers, B. M. and Zhou, B. P. (2009) Small C-terminal domain phosphatase enhances snail activity through dephosphorylation. *J. Biol. Chem.*, 284, 640–648.

30. Sapkota, G., Knockaert, M., Alarcon, C., Montalvo, E., Brivanlou, A. H. and Massague, J. (2006) Dephosphorylation of the linker regions of Smad1 and Smad2/3 by small C-terminal domain phosphatases has distinct outcomes for bone morphogenetic protein and transforming growth factor-beta pathways. *J. Biol. Chem.*, 281, 40412–40419.

31. Yeo, M., Lin, P. S., Dahmus, M. E. and Gill, G. N. (2003) A novel RNA polymerase II C-terminal domain phosphatase that preferentially dephosphorylates serine 5. *J. Biol. Chem.*, 278, 26078–26085.

32. Meyer, N. and Penn, L. Z. (2008) Reflecting on 25 years with MYC. *Nat. Rev. Cancer*, 8, 976–990.

33. Schlaeger, C., Longerich, T., Schiller, C., Bewerunge, P., Mehrabi, A., Toedt, G., Kleeff, J., Ehemann, V., Eils, R., Lichter, P. et al. (2008) Etiology-dependent molecular mechanisms in human hepatocarcinogenesis. *Hepatology*, 47, 511–520.

34. Li, S. P., Wang, H. Y., Li, J. Q., Zhang, C. Q., Feng, Q. S., Huang, P., Yu, X. J., Huang, L. X., Liang, Q. W. and Zeng, Y. X. (2001) Genome-wide analyses on loss of heterozygosity in hepatocellular carcinoma in Southern China. *J. Hepatol.*, 34, 840–849.

35. Yeo, M., Lee, S. K., Lee, B., Ruiz, E. C., Pfaff, S. L. and Gill, G. N. (2005) Small CTD phosphatases function in silencing neuronal gene expression. *Science*, 307, 596–600.